Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study in metastatic colorectal cancer
2006-004030-32Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic colon cancer (mCRC) comparing Campto + Fluorouracil + Folic acid + Erbitux with Campto + Fluorouracil + Folic acid + Avastin (2 arms). Primary endpoints: Progression-free survival and Objective response rate by RECIST. Started Nov 2006; status: completed.
02
Drugs
cetuximabbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2006-004030-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004030-32.